Background: Historically, thoracic reirradiation has been associated with high rates of toxicity from cumulative doses delivered to organs at risk (OARs). Conformal treatment in the form of proton therapy (PT) offers the opportunity to deliver definitive doses of radiotherapy with limited dose to surrounding OARs. We performed dosimetric analyses of patients undergoing thoracic re-irradiation with PT to identify parameters associated survival outcomes. Method: We identified patients with complete clinical and dosimetric information who received thoracic re-irradiation with PT on an IRB-approved prospective patient registry. Prior radiation courses were fused with PT plans to create composite plans, which were recalculated to an equivalent dose of 200 cGy per fraction (EQD2) using an a/b of 3. Toxicity was retrospectively assessed using CTCAE v4.0. Toxicity, disease control, and survival were estimated with the Kaplan-Meier method. The Cox proportional hazards model was used to estimate hazard ratios for univariate analysis (UVA), and significant dosimetric parameters were further assessed using cutpoint analysis. Patients were dichotomized based on these cutpoints, and survival differences were assessed using the log-rank test. Result: A total of 25 patients were included with a median age of 64 years (range 26-89). The majority of patients had non-small cell lung cancer (84%). Median PT re-irradiation dose was 6000 CGE (range 4000-6250) in 30 fractions (range 5-30 fractions). At a median followup of 17.5 months (range 1-34), one-year rates of local control, distant control, and overall survival, were 70.9%, 55.6%, and 71.2% respectively. No grade 4/5 toxicities were observed, and there were 5 late grade 3 events (2 non-malignant pleural effusions, 2 episodes of hemoptysis, 1 one esophageal stricture) with an estimated rate of 21% at 1 year. UVA revealed worse survival in patients with increasing maximum dose to the esophagus, carina, heart, pulmonary artery, and spinal cord, and increasing mean dose to the esophagus (p<0.05 for each). Patients who received a cumulative point max dose of 7500 cGy to the esophagus, 11620 cGy to the heart, 12000 cGy to the pulmonary artery, or 3250 mean dose to the esophagus had significantly worse survival than those who did not (all p<0.05). Conclusion: PT re-irradiation is a viable treatment option for patients with thoracic recurrences and offers excellent outcomes with limited toxicity. In this study, we identified dosimetric parameters associated with worse survival that can be used in treatment planning for recurrent disease.
Background: Historically, thoracic reirradiation has been associated with high rates of toxicity from cumulative doses delivered to organs at risk (OARs) . Conformal treatment in the form of proton therapy (PT) offers the opportunity to deliver definitive doses of radiotherapy with limited dose to surrounding OARs. We performed dosimetric analyses of patients undergoing thoracic re-irradiation with PT to identify parameters associated survival outcomes. Method: We identified patients with complete clinical and dosimetric information who received thoracic re-irradiation with PT on an IRB-approved prospective patient registry. Prior radiation courses were fused with PT plans to create composite plans, which were recalculated to an equivalent dose of 200 cGy per fraction (EQD2) using an a/b of 3. Toxicity was retrospectively assessed using CTCAE v4.0. Toxicity, disease control, and survival were estimated with the Kaplan-Meier method. The Cox proportional hazards model was used to estimate hazard ratios for univariate analysis (UVA), and significant dosimetric parameters were further assessed using cutpoint analysis. Patients were dichotomized based on these cutpoints, and survival differences were assessed using the log-rank test. Result: A total of 25 patients were included with a median age of 64 years (range 26-89). The majority of patients had non-small cell lung cancer (84%). Median PT re-irradiation dose was 6000 CGE (range 4000-6250) in 30 fractions (range 5-30 fractions). At a median followup of 17.5 months (range 1-34), one-year rates of local control, distant control, and overall survival, were 70.9%, 55.6%, and 71.2% respectively. No grade 4/5 toxicities were observed, and there were 5 late grade 3 events (2 non-malignant pleural effusions, 2 episodes of hemoptysis, 1 one esophageal stricture) with an estimated rate of 21% at 1 year. UVA revealed worse survival in patients with increasing maximum dose to the esophagus, carina, heart, pulmonary artery, and spinal cord, and increasing mean dose to the esophagus (p<0.05 for each). Patients who received a cumulative point max dose of 7500 cGy to the esophagus, 11620 cGy to the heart, 12000 cGy to the pulmonary artery, or 3250 mean dose to the esophagus had significantly worse survival than those who did not (all p<0.05). Conclusion: PT re-irradiation is a viable treatment option for patients with thoracic recurrences and offers excellent outcomes with limited toxicity. In this study, we identified dosimetric parameters associated with worse survival that can be used in treatment planning for recurrent disease. Background: Combined modality therapy is standard of care for patients with unrespectable locally advanced non-small cell, however, insufficient data are available regarding what is the best combination of chemotherapy and radiotherapy. Method: s: To evaluate the treatment results, study of 85 patients was randomly assigned to one of the two treatment arms. In the sequential arm, 45 patients had previously received sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal radiotherapy (RT). In the second concurrent arm, 40 patients received concomitant chemotherapy of cisplatine and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy of carboplatine and etoposide. We described all phases of the conformal RT. Result: s: From October 2005 to April 2008, 85 patients were enrolled. The median survival was 13 months for the patients in the sequential arm and 19 months for those in the concurrent treatment arm. The differences were statistically significant (log-rank test p¼0.0039) Figure 1 . The disease-free survival was 9 months in the sequential arm and 16 months in the concurrent treatment group. The differences were statistically significant (log-rank test p¼0.0023). Treatment-related toxicities were assessed according RTOG/EORTC criteria. Acute esophagitis and incidence of neutropenia were higher in the concurrent arm.. Grade 3 esophagitis was characteristic only for concurrent treatment and it was reason for radiotherapy interruption, but no longer than 7 days. Conclusion: s: Given the higher toxicity in the concurrent-consolidation schedule, it should be reserved for patients younger than 70 years, having good performance status and minimal weight loss. Keywords: conformal thoracic radiotherapy, sequential arm, concurrent consolidation arm Background: The current guidelines for the evaluation of mediastinal lymph nodes in the setting of lung cancer include EBUS with fineneedle aspiration and cytological evaluation to be enlarged on computed tomography (CT; short axis 1 cm). Optimal management of clinical stage IIIA (N2) NSCLC is controversial. This study is a systematic review and meta-analysis of published randomized control trials of multimodality management strategies for NSCLC. Method: We conducted a comprehensive literature search of the Pubmed databases for relevant studies comparing patients with stage IIIA (N2) NSCLC undergoing surgery alone, chemotherapy and/or radiotherapy alone, or surgical resection after neoadjuvant treatment with chemotherapy and/or radiotherapy. We estimated hazard ratios, odds ratios (ORs), and 95% confidence intervals (CIs) for survival data. Result: There was no significant difference in overall survival (OS) or progression-free survival (PFS) in stage IIIA (N2) NSCLC patients who received neoadjuvant chemotherapy or chemoradiotherapy prior to surgical
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